Lundwall K, et al. - Researchers evaluated how flow mediated vasodilation (FMD) is influenced by vitamin D treatment in patients with chronic kidney disease (CKD). They analyzed data from randomized controlled trials (RCTs) using any vitamin D compound, at any stage of CKD, with FMD as outcome. These studies were searched systematically through PubMed/Medline, Web of Science, Embase and Cochrane trials and reviews. They analyzed four trials, with 305 patients (mean age 44–65 years and all were in CKD 3 to 4). For treatment, cholecalciferol was used in one study and paricalcitol in the others. Study duration was 12–16 weeks. Findings demonstrated improved endothelial function, as measured by FMD, in association with short term treatment with vitamin D. This was indicative of positive impacts of vitamin D on vascular disease in CKD.